TCTMD

PROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study

Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent NATICK, ...
Medscape

Xience and Promus everolimus-eluting stents get FDA approval

Gaithersburg, MD - Seven months after an FDA advisory panel voted nine to one to recommend approval of the Xience V everolimus-eluting stent (Abbott Vascular), the FDA has granted marketing approval ...
FiercePharma

Promus PREMIER™ Everolimus-Eluting Platinum Chromium Stent System Receives CE Mark Approval

NATICK, Mass., Feb. 12, 2013 -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the ...
Medscape

Promus Element Plus Drug-Eluting Stent Approved

November 24, 2011 (Rockville, Maryland and Detroit, Michigan) — The US Food and Drug Administration (FDA) has approved the Promus Element Plus everolimus-eluting chromium platinum coronary stent ...
TCTMD

PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study

12-month clinical data demonstrate low adverse event rates for Boston Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent NATICK, Mass. and PARIS, Boston Scientific Corporation today announced ...